{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021256","form_type":"8-K","ticker":"PROK","cik":"0001850270","company_name":"PROKIDNEY CORP.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.226319+00:00","generated_at":"2026-06-15T04:53:34.480278+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ProKidney Q1 net loss $36.9M, cash $463.7M; Phase 2 REACT enrollment complete","bullets":["Net loss before noncontrolling interest $36.9M vs $67.5M in Q1 2022; R&D spend $25.6M.","Cash, cash equivalents and marketable securities $463.7M as of March 31, 2023.","Completed enrollment in REGEN-007 Phase 2 study (53 subjects); initial data expected late 2023.","Phase 3 proact 1 enrollment ongoing; interim data targeted by end of 2024.","Preparing to initiate proact 2 Phase 3 study in EU, Latin America, Asia Pacific in H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021256","json":"https://secwatch.observer/filing/0000950170-23-021256.json","markdown":"https://secwatch.observer/filing/0000950170-23-021256.md","text":"https://secwatch.observer/filing/0000950170-23-021256.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850270/000095017023021256/0000950170-23-021256-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850270/000095017023021256/prok-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:53:34.480278+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e71b0558e411f7a2951cc353e241af065e5a965b","claim":"PROKIDNEY CORP. reported the first quarter ended March 31, 2023 results: net income $36.9 million.","evidence_excerpt":"On May 11, 2023, ProKidney Corp. issued a press release to announce its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850270/000095017023021256/0000950170-23-021256-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"$36.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}